Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Heatmap
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
KRYS
#1045
Krystal Biotech, Inc. Common Stock
268.540
0
USD
-0.54%
Secteur:
Soins de Santé
Base:
USD
Devise de Profit:
USD
Range quotidien
Range Annuel
Changement quotidien
-0.54%
Changement Mensuel
+6.66%
Evolution sur 6 mois
+43.50%
Changement Annuel
+43.50%
Clôture Précédente
270.000
0
Open
268.490
0
Bid
Ask
Low
268.490
0
High
268.540
0
Volume
47
Marchés
Actions des Marchés US
Soins de Santé
KRYS
Open full chart
Financials
Overview
Relevé
Statistics
Quarterly
Annual
Value
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
28.81 M
28.9 M
28.94 M
29 M
29.23 M
—
Valuation ratios
Enterprise value
4.17 B
4.9 B
3.62 B
4.73 B
6.71 B
19.96 B
Price to earnings ratio
52.22
43.24
27.88
26.43
36.04
133.59
Price to sales ratio
16.04
16.11
11.41
14.1
18.98
60.59
Price to cash flow ratio
37.75
38.85
20.97
29.84
36.76
126.42
Price to book ratio
4.92
1.47
1.06
1.28
6.05
9.87
Enterprise value to EBITDA ratio
58.16
42.82
25.05
28.86
40.18
136.91
Profitability ratios
Return on assets %
0.04
0.03
0.03
0.06
0.04
0.17
Return on equity %
0.05
0.04
0.04
0.07
0.04
0.19
Return on invested capital %
36.97
26.31
28.8
57.98
35.83
148.92
Gross margin %
100
100
100
100
100
400
Operating margin %
45.36
41.02
40.93
42.3
41.49
165.75
EBITDA margin %
46.94
42.62
42.28
43.74
43
171.64
Net margin %
49.9
40.52
39.91
81.15
47.99
209.57
Liquidity ratios
Quick ratio
7.02
9.27
9.33
9.73
9.56
37.88
Current ratio
7.28
9.65
9.68
10.14
9.95
39.42
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.09
0.08
0.09
0.08
0.08
0.34
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
1.78
1.04
1.77
1.33
2.59
6.73
EBIT per share
1.39
1.21
1.32
1.39
1.48
5.4
EBITDA per share
1.44
1.26
1.36
1.43
1.54
5.59
Total debt per share
—
—
—
—
—
—
Cash per share
20.09
20.65
22.93
24.51
27.64
95.72
Net current asset value per share
24.95
25.67
28.28
31.03
34.21
119.19
Tangible book value per share
31.82
32.96
34.98
38.14
40.72
146.81
Working capital per share
21.52
23.01
25.36
27.97
30.77
107.11
Book value per share
31.82
32.96
34.98
38.14
40.72
146.81
Nouvelles
Palvella nomme Jennifer McDonough à la tête de l’accès au marché
OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development
Ocugen Stock Outlook: Balancing Cash Burn and Late-Stage Data
OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch
Why Is Krystal Biotech (KRYS) Down 11.5% Since Last Earnings Report?
Krishnan Krish S, président de Krystal Biotech, vend pour 6,58 millions de dollars d’actions KRYS
Krishnan Krish S, president of Krystal Biotech, sells $6.58 million in KRYS stock
Une directrice de Krystal Biotech vend pour 6,58 millions de dollars d’actions
Krystal Biotech director Krishnan sells $6.58 million in shares
Krystal Biotech à la conférence TD Cowen : croissance stratégique et défis
Krystal Biotech at TD Cowen Conference: Strategic Growth and Challenges
Daniel Janney vend des actions Krystal Biotech (KRYS) pour 3,25 millions $